PT -期刊文章盟尼尔·斯图尔特AU -史蒂夫·辛普森,小非盟-英格丽·范德美盟wood Ponsonby盟利暴雪AU -泰伦斯德怀尔盟Fotini皮塔饼AU -达里埃勒镇盟宝琳Ko盟-布鲁斯诉泰勒TI - Interferon-β和血清浓度交互调节援助- 10.1212 / WNL女士复发的风险。0 b013e31825fded9 DP - 2012年7月17日TA -神经首页病学第六PG - 254 - 260 - 79 IP - 3 4099 - //www.ez-admanager.com/content/79/3/254.short 4100 - //www.ez-admanager.com/content/79/3/254.full所以Neurology2012 7月17日;79 AB -目的:确定interferon-β(IFN-β)药物使用与维生素D的水平相关,是否两个交互在施加影响复发的风险。方法:前瞻性群组的178人与临床明确多发性硬化症(MS)住在南部的塔斯马尼亚在2002 - 2005年,人体内25 -羟维生素D血清25 (OH) D][每半年地测定,通过问卷调查与评估相关的因素,包括IFN-β治疗。结果:受试者报告IFN-β使用25 (OH) D的意思是要明显高于人没有(p & lt;0.001)。这是由个人日晒和IFN-β之间的交互,对待人实现三倍每小时25 (OH) D的阳光照射的人而不是治疗。25 (OH) D之间的关联,25-dihydroxyvitamin D不相差IFN-β疗法(p = 0.82)。25 (OH) D与降低复发风险只有在人IFN-β(p & lt;0.001)。人之间重要的是,IFN-β只是预防复发高25 (OH) D(风险比0.58 [HR][95%可信区间(CI) 0.35 - -0.98]),而在25 (OH) D-insufficient人,IFN-β复发风险增加(HR 2.01 (95% CI 1.22 - -3.32))。 Conclusion: In this study, we found that IFN-β therapy is associated with greater production of vitamin D from sun exposure, suggesting part of the therapeutic effects of IFN-β on relapse in MS may be through modulation of vitamin D metabolism. These findings suggest persons being treated with IFN-β should have vitamin D status monitored and maintained in the sufficiency range. Classification of evidence: This study provided Class III evidence that IFN-β is associated with reduced risk of relapse, and this effect may be modified by a positive effect of IFN-β on serum 25(OH)D levels. 25(OH)D=25-hydroxyvitamin D; 7-DHC=7-dehydrocholesterol; BMI=body mass index; CI=confidence interval; EDSS=Expanded Disability Status Scale; HR=hazard ratio; IFN-β=interferon-β; MS=multiple sclerosis; RRMS=relapsing-remitting multiple sclerosis